Form 4: Arcutis Biotherapeutics Director Sells Shares in Open Market Transaction

Director Terrie Curran sold 8,687 shares of Arcutis Biotherapeutics stock at an average price of $10.8482 on November 11, 2024.

Summary

• Terrie Curran, a director at Arcutis Biotherapeutics, sold 8,687 shares of common stock on November 11, 2024.
• The sale was executed at a weighted average price of $10.8482 per share.
• The prices ranged from $10.7542 to $10.97 per share.
• Following the transaction, Ms. Curran directly owns 10,139 shares of Arcutis Biotherapeutics stock.

Sentiment

Score: 5

Explanation: The document is a neutral disclosure of a stock sale by a director. It doesn't indicate positive or negative sentiment about the company's performance.

Industry Context

This is a routine disclosure of an insider transaction and is common for publicly traded companies. It does not indicate any specific trend in the pharmaceutical industry.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies in the US, and this transaction is consistent with typical insider trading activity.
• The sale of shares by a director is a common occurrence and does not necessarily indicate a negative outlook for the company.

Stakeholder Impact

• The sale of shares by a director may have a minor impact on shareholder sentiment, but it is not expected to significantly affect the company's operations or financial position.

Key Dates

Keywords

Arcutis Biotherapeutics, stock sale, insider trading, Form 4, director, Terrie Curran